Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathryn Thompson

Physician Assistant, Medical Shelton, CT Physician Assistant

NPI 1558529255 CMS profile 10695937

4 Corporate Dr, Suite 386, Shelton, CT 06484

Open in the dashboard

General payments

$11,585

574 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathryn Thompson of Shelton, CT is reported in the CMS Open Payments database as having received $11,585 across 574 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,564 113
2024 General $2,911 136
2023 General $2,871 138
2022 General $1,957 104
2021 General $1,282 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Thompson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kathryn Thompson were reported at $2,564. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kathryn Thompson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,282 $156 $41–$563 $132
2022 $1,957 $185 $55–$649 $149
2023 $2,871 $199 $58–$717 $160
2024 $2,911 $206 $62–$740 $164
2025 $2,564 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $1,189 60 payments
  2. Janssen Biotech, Inc. $1,130 47 payments
  3. AbbVie, Inc. $1,047 57 payments
  4. Incyte Corporation $1,047 49 payments
  5. Pfizer Inc. $1,045 54 payments
  6. Sun Pharmaceutical Industries Inc. $747 33 payments
  7. Genzyme Corporation $643 28 payments
  8. Ortho Dermatologics, a division of Bausch Health US, LLC $593 34 payments
  9. Regeneron Healthcare Solutions, Inc. $538 27 payments
  10. Galderma Laboratories, L.P. $485 39 payments
  11. Other $3,122 146 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,330 571 payments
  2. Education $255 3 payments
Products named General payments · program years 2021–2025
  1. OPZELURA $1,047 49 payments
  2. TREMFYA $1,042 39 payments
  3. TALTZ $944 54 payments
  4. DUPIXENT $852 37 payments
  5. CIBINQO $714 37 payments
  6. EUCRISA $608 41 payments
  7. SKYRIZI $568 26 payments
  8. VTAMA $530 21 payments
  9. SOTYKTU $451 16 payments
  10. LITFULO $425 16 payments
  11. Other $6,095 344 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,050

Median for Physician Assistant: 241

Drug cost

$477,811

Median for Physician Assistant: $4,110

Branded share of claims

9.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 15 $299,616
Taltz Autoinjector Ixekizumab Brand 11 $76,350
Dupixent Pen Dupilumab Brand 12 $44,905
Opzelura Ruxolitinib Phosphate Brand 11 $21,282
Jublia Efinaconazole Brand 13 $12,737
Betamethasone Dipropionate Generic 106 $3,476
Clobetasol Propionate Generic 74 $2,582
Calcipotriene Generic 12 $2,360
Triamcinolone Acetonide Generic 203 $2,348
Fluorouracil Generic 30 $2,222

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$57,472

Of which drugs: $23

Medicare patients

453

Average age 75

Services billed

1,510

327 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 46%
Ischemic heart disease 24%
Osteoporosis 22%
Cancer 20%
Diabetes 18%
Depression 16%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 32 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $480
$480 — —
OPZELURA
  • Incyte Corporation $254
$254 11 —
SKYRIZI
  • AbbVie, Inc. $230
$230 15 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $120
  • GENZYME CORPORATION $108
$228 12 —
LITFULO
  • PFIZER INC. $197
$197 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

574 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record